Sound Science Policy Requires Better Data Management

AUTHOR: DARYL E. CHUBIN AND ELIZABETH M. ROBINSON, p.11 How can Congress ensure that the best science continues to be funded, and that a full portfolio of research is maintained? The answer, in large part, is to collect sufficient and relevant data on the research enterprise in the United States, and to see that it is circulated efficiently among decision makers. The information should include, at a minimum, details on how research moneys are spent, on the scientific work force, on the key ele

Written byDaryl Chubin
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

AUTHOR: DARYL E. CHUBIN AND ELIZABETH M. ROBINSON, p.11

How can Congress ensure that the best science continues to be funded, and that a full portfolio of research is maintained? The answer, in large part, is to collect sufficient and relevant data on the research enterprise in the United States, and to see that it is circulated efficiently among decision makers.

The information should include, at a minimum, details on how research moneys are spent, on the scientific work force, on the key elements of the research enterprise itself (how scientists spend their time, and what equipment and facilities they must have), and on the measurable outcomes of federally funded research.

A recent study by the Office of Technology Assessment, requested by Congress, concluded that today's politically competitive environment requires that Congress set priorities in allocating research funds. A rapid growth in the number of researchers, tight constraints on federal ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies